Generic Name and Formulations:
Cisatracurium besylate 2mg/mL, 10mg/mL (for ICU use only); soln for IV infusion.
Indications for NIMBEX:
As an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the ICU.
See literature. Individualize. Initial dose: 0.15mg/kg or 0.2mg/kg; duration of action with propofol anesthesia: 55 minutes and 61 minutes, respectively. Maintenance: 0.03mg/kg; generally required 40–50 minutes after initial dose of 0.15mg/kg and 50–60 minutes after initial dose of 0.2mg/kg. No adjustment in initial dose necessary when cisatracurium is given shortly after initiation of volatile agents. In long surgical procedures, during enflurane and isoflurane anesthesia, less frequent maintenance dosing or lower maintenance dose may be necessary. Infusion in OR: after initial bolus dose, a diluted solution may be given by continuous infusion during extended surgical procedures. Under opioid/nitrous oxide/oxygen anesthesia: a rate of 1–2mcg/kg/min should be adequate to maintain continuous neuromuscular block. Under isoflurane/enflurane anesthesia: reduce rate by 30–40%. Infusion in ICU: 3mcg/kg/min.
<1month: not recommended. Individualize. 1–23months: initial dose: 0.15mg/kg given over 5–10 seconds during either halothane or opioid anesthesia; duration of action: approx. 43 minutes. 2–12yrs: initial doses: 0.1–0.15mg/kg given over 5–10 seconds during halothane or opioid anesthesia; duration of action: 0.1mg/kg: approx. 28 minutes, 0.15mg/kg: approx. 36 minutes. Infusion in OR: >2yrs: after initial bolus dose, a diluted solution may be given by continuous infusion during extended surgical procedures. Under opioid/nitrous oxide/oxygen anesthesia: a rate of 1–2mcg/kg/min should be adequate to maintain continuous neuromuscular block. Under isoflurane/enflurane anesthesia: reduce rate by 30–40%.
Premature infants (10mL vial contains benzyl alcohol).
To be administered under the supervision of experienced clinicians. Have intubation, artificial respiration, oxygen therapy and reversal agents available. Not recommended for rapid sequence endotracheal intubation. Neuromuscular diseases (eg, myasthenia gravis, myasthenic syndrome). Burn patients. Patients with hemiparesis or paraparesis; neuromuscular monitoring should be performed on non-paretic limb. Acid-base and/or serum electrolyte abnormalities. Be prepared to recognize and treat malignant hyperthermia. ICU: monitor neuromuscular function; if no response elicited, discontinue until response returns. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Nondepolarizing skeletal muscle relaxant.
May be potentiated by isoflurane, enflurane, antibiotics (eg, aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, quinidine. May be antagonized by chronically administered phenytoin or carbamazepine.
Bradycardia, hypotension, flushing, bronchospasm, rash, anaphylactic reactions, prolonged neuromuscular block, inadequate neuromuscular block, muscle weakness, myopathy.
Single-dose vial (2mg/mL)—5mL; Single-dose vial (10mg/mL)—20mL; Multi-dose vial (2mg/mL)—10mL (contains benzyl alcohol)
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Congress Passes Bill to Fight Opioid Crisis
- Digital Cognitive Therapy Eases Daytime Effects of Insomnia
- Models Predict Intracerebral Hemorrhage Growth
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience